# Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator

> **NCT02413047** · NA · TERMINATED · sponsor: **Indiana University** · enrollment: 3 (actual)

## Conditions studied

- Inflammatory Bowel Disease
- Ulcerative Colitis
- Crohn's Disease

## Interventions

- **DRUG:** Azathioprine
- **DRUG:** 6 mercaptopurine
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02413047
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** physician decision to stop study early due to low enrollment
- **Last updated:** 2019-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02413047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02413047, "Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02413047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*